Qiuf Trump gives detailed account of assassination attempt in lengthy RNC acceptance speech
One person was killed in a shooting near W. Fond du Lac Ave. and W. Burleigh St. T
stanley website uesday,
stanley thermos mug police say.The Milwaukee Police Department says it was called to the scene around 5:30 Tuesday morning. Officers say a 39-year-old victim was pronounced dead at the scene. They re looking for an unknown suspect.On Tuesday afternoon, the Milwaukee County Medical Examiner s Office identified the victim as 39-year-old Bobby Howard.Anyone with any information is asked to call the Milwaukee Police Department at 414-935-7360 or, to remain anonymous, call Crime Stoppers at 414-224-TIPS Talk to us: Hey there! At TMJ4 News, were all about listening to our audience and tackling the stuff that really matters to you. Got a story idea, tip, or just want to chat about this piece Hit us up using the form below. For more ways to get in touch, head over to tmj4/tips. Its about time to watch on your time. Stream local news and weather 24/7 by searching for TMJ4 on your device.Available for download on Roku, Apple TV, Amazon Fire TV, a
stanley quencher nd more.Report a typo or error // Submit a news tip Rkly Bronze Fonz vandalized: Iconic statue coated in black substance
The FDA on Monday approved an experimental drug that aims to slow the progression of Alzheimer s disease, despite the fact that a key FDA panel late last year said that questions remain about its effectiveness.The FDA on Monday approved the use of aducanumab in patients in the early stages of Alzheimer s. Drugmakers Biogen and Eisai say the drug doesn t just address symptoms but actually slows the progression timeline of the disease.Monday marks the
stanley cup first time that the FDA has approved a new Alzheimer s drug in nearly 20 years.Aducanumab s approval
stanley vaso faced several hurdles along the way.NPR reports that the drug is designed to reduce the building up of amyloid plaques that grow in the brains of
stanley cup becher Alzheimer s patients. While studies have shown that the drug is effective in reducing plaque buildup, it s unclear if reducing that plaque can improve a person s cognitive function.According to NPR, drugmakers ended two major studies of aducanumab when preliminary data suggested that the drug wasn t working. However, the companies decided to seek approval when a re-analysis of the data produced a more favorable result.Ultimately, the FDA was presented with results from two major studies 鈥?one which showed the drug work, another which showed the drug didn t work.Aducanumab s approval hit another snag in November when the FDA s Peripheral and Central Nervous System Drugs Advisory Committee was asked if it was reasonable to consider the data from one positive study for the drug s effectivene
